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Abstract
Epigenetic silencing of regulatory genes by aberrant methylation contributes to tumorigenesis.
DNA methyltransferase inhibitors (DNMTI) represent promising new drugs for anti-cancer
therapies. The DNMTI 5-Azacytidine is effective against myelodysplastic syndrome, but induces
switching of latent to lytic Epstein-Barr virus (EBV) in vitro and results in EBV DNA demethylation
with the potential of induction of lytic EBV in vivo. This is of considerable concern given that
recurrent lytic EBV has been linked with an increased incidence of EBV-associated lymphomas.
Based on the distinct properties of action we hypothesized that the newer DNMTI Zebularine
might differ from 5-Azacytidine in its potential to induce switching from latent to lytic EBV. Here
we show that both 5-Azacytidine and Zebularine are able to induce expression of E-cadherin, a
cellular gene frequently silenced by hypermethylation in cancers, and thus demonstrate that both
DNMTI are active in our experimental setting consisting of EBV-harboring Burkitt's lymphoma
Akata cells. Quantification of mRNA expression of EBV genes revealed that 5-Azacytidine induces
switching from latent to lytic EBV and, in addition, that the immediate-early lytic infection
progresses to early and late lytic infection. Furthermore, 5-Azacytidine induced upregulation of the
latent EBV genes LMP2A, LMP2B, and EBNA2 in a similar fashion as observed following switching of
latent to lytic EBV upon cross-linking of the B-cell receptor. In striking contrast, Zebularine did not
exhibit any effect neither on lytic nor on latent EBV gene expression. Thus, Zebularine might be
safer than 5-Azacytidine for the treatment of cancers in EBV carriers and could also be applied
against EBV-harboring tumors, since it does not induce switching from latent to lytic EBV which
may result in secondary EBV-associated malignancies.
Findings
Abnormal hypermethylation of the promoters of cancer-
related or tumor suppressor genes is commonly found in
primary neoplasms and tumor cell lines [1]. Thus, phar-
macologic inhibition of DNA methylation could provide
an effective means of epigenetic anti-cancer treatment.
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Indeed, 5-Azacytidine, a pyrimidine ring analogue of cyti-
dine and DNA methylase inhibitor (DNMTI), has proven
to be effective against myelodysplastic syndrome in a
phase III randomized clinical trial [2]. 5-Azacytidine
forms covalent complexes with cytosine- [C5]-specific
DNA methyltransferases and inhibits their activity [3]. In
addition, 5-Azacytidine is activated by uridine-cytidine
kinase and can be incorporated into both RNA and DNA.
Incorporation into RNA interferes with protein transla-
tion [4], which is the cause of 5-Azacytidine toxicity. This
substance is also characterized by a low stability in aque-
ous solution [5,6].
Different types of cancers including Burkitt's lymphoma
(BL) and nasopharyngeal carcinoma (NPC) harbor latent
Epstein Barr virus (EBV) [7] and maintenance of latent
EBV is partially mediated by hypermethylation of the EBV
genome. Thus, it is not surprising that 5-Azacytidine
induces switching of latent to lytic EBV in vitro [8-11] and
results in EBV DNA demethylation in NPC patients with
the potential of induction of lytic EBV [12]. Recurrent lytic
EBV caused by chronic disruption of EBV latency due to
long-lasting methotrexate treatment in EBV-carrying rheu-
matoid arthritis and polymyositis patients has been
linked with an increased incidence of EBV-associated lym-
phomas [13]. Therefore, since DNMTI need to be admin-
istered for long periods of time to treat cancers, DNMTI
with the potential to induce lytic EBV could have detri-
mental consequences in EBV carriers and be inappropriate
to combat EBV-carrying tumors.
Zebularine (1-(β-D-ribofuranosyl)-1,2-dihydropyrimi-
din-2-one), a newer cytidine analog containing a 2-(1H)-
pyrimidinone ring, acts as 5-Azacytidine by forming cova-
lent complexes with DNMT [14], and in addition acts as
transition state analog inhibitor of cytidine deaminase by
binding covalently at the active site [15]. In comparison to
5-Azacytidine, Zebularine has little toxicity; shows
increased stability [16,17], and targets preferentially
tumor cells [18]. Hence, Zebularine promises to be a bet-
ter drug than 5-Azacytidine for epigenetic therapy of can-
cer. Nevertheless, the potential of Zebularine in inducing
lytic EBV is unknown.
Based on the distinct properties we hypothesized that
Zebularine might differ from 5-Azacytidine in its potential
to induce lytic EBV. Thus, we compared the effects of both
DNMTI on EBV latency in the BL cell line Akata, a well-
established model to study switching of latent to lytic EBV
which also allows the study of DNMTI effects on cellular
genes silenced in cancer cells.
We first determined the concentrations of 5-Azacytidine
and Zebularine without cytotoxicity within 48 h. The
highest sub-toxic concentration of 5-Azacytidine was 1
μM (Fig. 1a) and of Zebularine was between 0.03 mM and
0.1 mM (Fig. 1b).
To validate our experimental conditions we next meas-
ured in Akata cells the expression of cellular genes known
to be reactivated by Zebularine in other tumor cell lines
including  CDKN1A,  CDKN1B  and  CDKN2A  genes
[18,19]. Using quantitative real-time PCR (qRT-PCR),
expression of these cyclin-dependent kinases (CDK) was
already detectable in the non-treated cells and did not fur-
ther increase upon treatment neither with 5-Azacytidine
nor Zebularine (not shown) suggesting that in the p53
mutated Akata cells [20] these CDKs are not silenced by
hypermethylation. This did not hold true for E-cadherin
(CDH1). E-cadherin mediates cell adhesion and loss of its
expression by hypermethylation [21] is responsible for
increased cancer invasiveness and metastasis [22]. CDH1
expression is reactivated by 5-aza-2'-deoxycytidine treat-
ment in the BL cell line Raji [23]. We therefore measured
the expression of CDH1 by qRT-PCR in treated Akata cells
(Fig. 1c and 1d). Expression of CDH1 was not detectable
in non-treated Akata cells. Treatment with 1.0 μM 5-Aza-
cytidine resulted in a 30-fold induction of CDH1 mRNA
expression after 48 h, that increased to 150-fold at 72 h.
At a concentration of 0.5 μM, 5-Azacytidine showed a
maximal 30-fold activation of CDH1 after 72 h and at 0.1
μM had no significant effect on expression of CDH1
mRNA even after 72 h. Zebularine (100 μM) induced a
50-fold activation of CDH1 after 120 h (5 days), that was
sustained and increased to 100-fold after 10 days of con-
tinuous Zebularine treatment. This delayed effect was
expected since Zebularine follows a slower kinetic with
maximal effects later than 5-Azacytidine also in other cel-
lular backgrounds [18,24]. These results show that 5-Aza-
cytidine and Zebularine are able to induce expression of
CDH1 known to be frequently silenced by hypermethyla-
tion [22,25], and demonstrate that both DNMTI are active
in our experimental setting.
The first step in activation of lytic EBV infection is the
expression of the immediate-early lytic EBV gene BZLF1.
Zta, the product of BZLF1, is a transcription factor that
regulates the expression of early lytic EBV genes, and acti-
vates the lytic EBV gene expression program [26]. To deter-
mine the effects of 5-Azacytidine and Zebularine on
switching latent to lytic EBV in Akata cells, we measured
the mRNA expression of BZLF1 by qRT-PCR in Akata cells
treated with increasing concentrations of 5-Azacytidine at
48 h and 72 h and for Zebularine at up to 10 days. 1 μM
5-Azacytidine was able to induce activation of BZLF1
mRNA expression (Fig 1e). Induction of BZLF1 mRNA
was robust, reaching about 280-fold over mock-treated
cells. 5-Azacytidine concentrations lower than 1 μM did
not have a significant effect on BZLF1 mRNA expression.
Cytotoxic concentrations higher than 1 μM also activatedMolecular Cancer 2007, 6:3 http://www.molecular-cancer.com/content/6/1/3
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Response of Burkitt's lymphoma Akata cells to 5-Azacytidine and Zebularine treatment Figure 1
Response of Burkitt's lymphoma Akata cells to 5-Azacytidine and Zebularine treatment. (a, b) Determination 
of non-toxic concentrations for Akata treatment in vitro with 5-Azacytidine (a) and Zebularine (b). 5 × 105 viable cells 
were seeded in 1 ml medium with increasing 5-Azacytidine or Zebularine concentrations. Living cells (trypan-blue exclusion) 
were then counted after 48 h and 72 h. The highest non-toxic-concentrations are: 1 μM 5-Azacytidine (a) and 100 μM for 
Zebularine (b). (c, d) Expression of E-cadherin (CDH1) normalized to HMBS. Treatment with 1.0 μM 5-Azacytidine 
resulted in a 30-fold induction of CDH1 expression after 48 h (c), and with slower kinetics 100 μM Zebularine induced a 60-
fold activation after 120 h and was sustained after 8 days of continuous Zebularine treatment (d). (e, f) BZLF1 expression 
indicating initiation of lytic EBV was observed after 1 μM 5-Azacytidine treatment (e), while 30 μM or 100 μM Zebularine do 
not activate BZLF1 expression, even after 8 days (f). Data in a-f are given as means ± SD from three independent experiments 
(g, h) Expression of early and late lytic EBV genes. Treatment with 5-Azacytidine results in increased expression of both 
EBV early and late antigens (g). Treatment with Zebularine did not show any significant increase of expression of early or late 
lytic antigens (h). (i, j) Expression of latent EBV genes LMP2A and EBNA2 increased around 10-fold upon treatment with 
1.0 μM 5-Azacytidine. EBNA2 expression increased about 60-fold by 0.5 μM and 1.0 μM 5-Azacytidine at 48 h. The lowest 5-
Azacytidine concentration used (0.1 μM) was also able to induce a 50-fold increase of EBNA2 expression at 72 h (i). LMP2B did 
show a maximal increase when treated with 1 μM 5-Azacytidine. (i). Treatment with Zebularine concentrations between 0.03 
mM and 1 mM did not have a significant effect on LMP2B and EBNA2 gene expression up to 72 h (j). Data in g-j are given as 
means of three independent experiments.
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BZLF1  mRNA expression to even a greater extent (not
shown). Treatment of Akata cells with 100 μM Zebularine
did not result in induction of BZLF1  mRNA (Fig. 1f).
Higher concentrations of Zebularine in the range of 1 mM
to 3 mM resulted in a 10-fold induction of BZLF1 mRNA
(not shown), likely due to stress response to cytotoxic
insult, rather than specific activation of BZLF1  mRNA
expression. These results confirm that 5-Azacytidine initi-
ates lytic EBV infection at sub-toxic concentrations and in
addition demonstrate that by contrast treatment with
Zebularine up to 10 days does not provoke any change in
BZLF1 mRNA expression levels in Akata cells.
To elucidate whether activation of the master regulatory
lytic EBV gene BZLF1 by 5-Azacytidine is followed by acti-
vation of early and late lytic EBV genes and whether Zebu-
larine does activate other lytic EBV genes independently of
BZLF1 we also quantified mRNA expression of BALF1,
BMRF1, and BXLF2 (Fig. 1g and 1h). BALF1 codes for an
anti-apoptotic cytoplasmic early lytic antigen, BMRF1 for
the early antigen-diffuse EA-D, and BXLF2 for the late lytic
antigen glycoprotein gp85. Treatment of Akata cells with
1 μM 5-Azacytidine resulted in increased expression of
both early and the late lytic antigens at 48 h with surpris-
ingly similar kinetics. Even 0.1 μM 5-Azacytidine was able
to increase mRNA expression of lytic EBV genes by a ten-
fold at 72 h. By contrast, no expression of early or late lytic
EBV genes was measurable in Akata cells treated with
Zebularine. Even treatment with 1 mM Zebularine; a con-
centration that apparently did induce expression of BZLF1
mRNA after 48 h, was not able to activate mRNA expres-
sion of other lytic EBV genes. This supports our above
mentioned interpretation that expression of BZLF1
mRNA at a 1 mM Zebularine dose was not a specific event
with subsequent full lytic EBV gene expression. These
results indicate that 5-Azacytidine activates all three
phases of lytic EBV infection and evidence that Zebularine
does not induce switching from latent to lytic EBV.
The failure of Zebularine to induce switching from latent
to lytic EBV could be due to either having no effect on EBV
at all or due to reinforcement of latent EBV gene expres-
sion. Thus, we compared the quantitative mRNA expres-
sion of latent EBV genes before and during treatment with
5-Azacytidine or Zebularine. Treatment of Akata cells with
1.0  μM and 0.5 μM 5-Azacytidine increased LMP2A
mRNA expression by 10-fold at 48 h and at 72 h, respec-
tively, and LMP2B mRNA by around 10-fold at 48 h (1.0
μM). The effects on EBNA2 mRNA expression were more
marked with an increase by 60-fold using 5-Azacytidine at
0.5 μM and by 400-fold at 1.0 μM at 48 h. Even the lowest
5-Azacytidine concentration used (0.1 μM) was able to
induce a 30-fold increase of EBNA2 mRNA expression at
72 h (Fig. 1i). We and others have previously shown a
similar activation of LMP2 and EBNA2 upon induction of
lytic EBV by IgG cross-linking in Akata cells [27,28]. In
striking contrast, none of the tested Zebularine concentra-
tions exhibited an effect on latent EBV gene expression
(Fig. 1j), suggesting that the failure of Zebularine to
induce switching of latent to lytic EBV is not due to rein-
forcement of latent EBV gene expression. We therefore
conclude that Zebularine has no effect on EBV gene
expression in Akata cells, neither on lytic nor latent.
In the BL cell line Akata, both 5-Azacytidine and Zebular-
ine are able to reactivate an important regulatory gene like
E-cadherin, which when silenced by hypermethylation
contributes to cell malignancy. Hypermethylation is also
an important regulatory mechanism of EBV latency. This
is emphasized by the fact that EBV can modulate the activ-
ity of DNA methyltransferases through the latent mem-
brane protein LMP1, that can induce activation of DNA
methyltransferases in epithelial carcinoma and lead to
silencing of E-cadherin expression [29]. 5-Azacytidine and
Zebularine act by different mechanisms [24]. Impor-
tantly, here we show that Zebularine, unlike 5-Azacyti-
dine, does not disrupt EBV latency. Thus, Zebularine
might be safer than 5-Azacytidine for the epigenetic treat-
ment of cancers in EBV carriers and could also be
employed to treat EBV-harboring tumors, since it does not
induce switching from latent to lytic EBV a process linked
to secondary EBV-associated malignancies.
Materials and methods
Cell lines
The human BL cell line Akata was cultured in RPMI 1640
medium (Invitrogen, Basel, Switzerland), supplemented
with 10% heat-inactivated fetal calf serum, L-Glutamine
(1%), penicillin (1 U/ml), streptomycin (1 μg/ml). The
human bladder carcinoma cell line T24 was cultured in
McCoy's medium supplemented with 10% fetal calf
serum, L-Glutamine (1%), penicillin (1 U/ml), strepto-
mycin (1 μg/ml). The cells were grown at 37°C in 5% CO2
humidified atmosphere and split every third day. Akata
cell line was a kind gift from Dr. A. Bell (Birmingham,
UK), and T24 cell line was a kind gift from Dr. H.
Wunderli-Allenspach (ETH Zürich, Switzerland). The
optimal cell density (5 × 105 cells/ml) for experiments
with Akata cells allowed logarithmic cell growth over the
observation period.
DNA-methylase inhibitor treatments
5-Azacytidine was purchased from Sigma-Aldrich Chemie
Gmbh (Buchs, Switzerland) as lyophilized powder and
stored at -20°C. 5-Azacytidine solution was prepared
fresh for each experiment in PBS at a concentration of 2.4
mg/ml (10 mM) and sterile filtered. Zebularine was pur-
chased from Calbiochem (Merk Biosciences, Darmstadt,
Germany) and stored at 4°C. Zebularine was dissolved in
PBS at a concentration 28.5 mg/ml (120 mM), sterile fil-Molecular Cancer 2007, 6:3 http://www.molecular-cancer.com/content/6/1/3
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tered and stored at 4°C. For each experiment with Akata
cells, viable cells were counted by trypan-blue exclusion
method and resuspended in fresh medium at 0.5 × 106
cells/ml. T24 cell line experiments were performed as
described [18].
Quantitative real-time PCR analysis
RNA isolation was then performed by using Rneasy Mini
Kit (Qiagen, Hombrechtikon, Switzerland) according to
the manufacturer's protocol. Contaminating genomic
DNA was removed by using DNA-free (Ambion Europe,
Huntingdon, UK) according to the manufacturer's proto-
col. The RNA concentration was measured with an Eppen-
dorf Bio Photometer (Vaudaux Eppendorf, Dübendorf,
Switzerland). cDNA was prepared by reverse transcription
of total RNA using the Omniscript RT-Kit (Quiagen) fol-
lowing the manufacturer's protocol. qRT-PCR was per-
formed in a reaction volume of 10 μl with the ABI-
TaqMan Master Mix with uracil-N-glycosylase (Applied
Biosystems, Rotkreuz, Switzerland). Sequence informa-
tion for the Taqman systems will be furnished upon
request. mRNA expression of the target genes was normal-
ized to the expression of the housekeeping gene HMBS
[30]. The normalized transcription values correspond to
2-C
T
(EBV)-C
T
(HMBS) = 2-ΔC
T, where CT is the cycle threshold
number that quantifies the target present.
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